Is rational antipsychotic polytherapy feasible? A selective review

Current Psychiatry Reports

Volumn 14, Issue 3, 2012, Pages 244-251

  Kroken, Rune Andreas ^a   Johnsen, Erik ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

Antipsychotic; Aripiprazole; Clozapine; Dopamine; Haloperidol; Polypharmacy; Polytherapy; Rational; Schizophrenia; Translational; Treatment refractory; Treatment resistant

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CHLORPROMAZINE; CHOLESTEROL; CLOZAPINE; GLUCOSE; HALOPERIDOL; NEUROLEPTIC AGENT; PLACEBO; PRECLAMOL; PROLACTIN; QUETIAPINE; RISPERIDONE; SULPIRIDE;

ADD ON THERAPY; CHOLESTEROL METABOLISM; DOPAMINE RECEPTOR BLOCKING; DOPAMINERGIC TRANSMISSION; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYNDROME; FEASIBILITY STUDY; GALACTORRHEA; GLUCOSE METABOLISM; HUMAN; HYPERPROLACTINEMIA; HYPOGONADISM; INFERTILITY; METABOLIC DISORDER; NEUROBIOLOGY; NONHUMAN; OSTEOLYSIS; OUTCOME ASSESSMENT; POLYPHARMACY; PRACTICE GUIDELINE; PROLACTIN BLOOD LEVEL; PSYCHOSOCIAL CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG THERAPY, COMBINATION; HALOPERIDOL; HUMANS; PIPERAZINES; PROLACTIN; QUINOLONES; SCHIZOPHRENIA;

EID: 84861097976     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-012-0266-y     Document Type: Review

References (66)

1. Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. How effective are second-generation antipsychotic drugs? A metaanalysis of placebo-controlled trials. Mol Psychiatry. 2009;14 (4):429-47.
2. Davis JM, Schaffer CB, Killian GA, Kinard C, Chan C. Important issues in the drug treatment of schizophrenia. Schizophr Bull. 1980;6(1):70-87. (Pubitemid 10066395)
3. Meltzer HY. Treatment-resistant schizophrenia - the role of clozapine. Curr Med Res Opin. 1997;14(1):1-20. (Pubitemid 28080714)
4. Centorrino F, Ventriglio A, Vincenti A, Talamo A, Baldessarini RJ. Changes in medication practices for hospitalized psychiatric patients: 2009 versus 2004. Hum Psychopharmacol Clin Exp. 2010;25(2):179-86.
5. Edlinger M, Hausmann A, Kemmler G, Kurz M, Kurzthaler I, Walch T, et al. Trends in the pharmacological treatment of patients with schizophrenia over a 12 year observation period. Schizophr Res. 2005;77:25-34. (Pubitemid 40957058)
6. Correll CU. Antipsychotic polypharmacy, part 1: shotgun approach or targeted cotreatment? J Clin Psychiatry. 2008;69 (4):674-5. (Pubitemid 351792345)
7. Goodwin G, Fleischhacker W, Arango C, Baumann P, Davidson M, de Hert M, et al. Advantages and disadvantages of combination treatment with antipsychotics: ECNP Consensus Meeting, March 2008, Nice. Eur Neuropsychopharmacol. 2009;19 (7):520-32.
8. Kroken R, Johnsen E, Ruud T, Wentzel-Larsen T, Jorgensen H. Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study. BMC Psychiatry. 2009;9:24.
9. Barnes TR, Paton C. Antipsychotic polypharmacy in schizophrenia: benefits and risks. CNS Drugs. 2011;25(5):383-99.
10. Buchanan RW, Kreyenbuhl J,Kelly DL, Noel JM, BoggsDL, Fischer BA, et al. The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements. Schizophr Bull. 2010;36(1):71-93.
11. Lehman A, Lieberman J, Dixon L, McGlashan T, Miller A, Perkins D, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161:1-56.
12. National Institute of Clinical Excellence (NICE). The NICE Guideline on core interventions in the treatment and management of schizophrenia in adults in primary and secondary care - updated edition. In: NHS; 2009.
13. Dougherty D, Conway PH. The "3 T's" road map to transform US Health Care. JAMA. 2008;299(19):2319-21.
14. Honer WG, Procyshyn RM, Chen EY, MacEwan GW, Barr AM. A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacy. J Psychiatry Neurosci. 2009;34(6):433-42.
15. Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov. 2004;3(4):353-9. (Pubitemid 38499762)
16. Abi-Dargham A, Laruelle M. Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. European Psychiatry. 2005;20(1):15-27. (Pubitemid 40092387)
17. Lieberman JA, Bymaster FP, Meltzer HY, Deutch AY, Duncan GE, Marx CE, et al. Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev. 2008;60(3):358-403.
18. Keshavan MS, Tandon R, Boutros NN, Nasrallah HA. Schizophrenia, "just the facts": what we know in 2008: Part 3: Neurobiology. Schizophr Res. 2008;106(2-3):89-107.
19. Preskorn S, Lacey R. Polypharmacy: when is it rational? J Psychiatr Pract. 2007;13(2):97-105. (Pubitemid 46588311)
20. Wheeler A, Humberstone V, Robinson G. Outcomes for schizophrenia patients with clozapine treatment: how good does it get? J Psychopharmacol. 2009;23(8):957-65.
21. Meltzer HY, Bastani B, Kwon KY, Ramirez LF, Burnett S, Sharpe J. A prospective study of clozapine in treatment-resistant schizophrenic patients. Psychopharmacology. 1989;99:S68-72. (Pubitemid 19244143)
22. Kane J, Correll C, Goff D, Kirkpatrick B, Marder S, Vester- Blokland E, et al. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry. 2009;70 (10):1348-57.
23. Correll C, Rummel-Kluge C, Corves C, Kane J, Leucht S. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull. 2009;35(2):443-57.
24. Kotler M, Strous RD, Reznik I, Shwartz S, Weizman A, Spivak B. Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology. Int Clin Psychopharmacol. 2004;19(1):23-6. (Pubitemid 38114620)
25. Higashima M, Takeda T, Nagasawa T, Hirao N, Oka T, Nakamura M, et al. Combined therapy with low-potency neuroleptic levomepromazine as an adjunct to haloperidol for agitated patients with acute exacerbation of schizophrenia. European Psychiatry. 2004;19 (6):380-1. (Pubitemid 39207968)
26. Laruelle M. Imaging dopamine transmission in schizophrenia. A review and meta-analysis. Q J Nucl Med. 1998;42(3):211-21. (Pubitemid 28529874)
27. Howes O, Egerton A, Allan V, McGuire P, Stokes P, Kapur S. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr Pharm Des. 2009;15(22):2550-9.
28. Stone JM, Raffin M, Morrison P, McGuire PK. Review: the biological basis of antipsychotic response in schizophrenia. J Psychopharmacol. 2010;24(7):953-64.
29. Meltzer HY. An atypical compound by any other name is still a. Psychopharmacology. 2000;148:16-9. (Pubitemid 30062466)
30. Barnes TR, The Schizophrenia Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2011;25(5):567-620.
31. Wolff-Menzler C, Hasan A, Malchow B, Falkai P, Wobrock T. Combination therapy in the treatment of schizophrenia. Pharmacopsychiatry. 2010;43(4):122-9.
32. Wang J, Omori I, Fenton M, Soares B. Sulpiride augmentation for schizophrenia. Cochrane Database Syst Rev. 2010;1.
33. Cipriani A, Boso M, Barbui C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst Rev. 2009(3).
34. Genc Y, Taner E, Candansayar S. Comparison of clozapineamisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study. Adv Ther. 2007;24(1):1-13. (Pubitemid 46700860)
35. Zink M, Kuwilsky A, Krumm B, Dressing H. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial. J Psychopharmacol. 2009;23(3):305-14.
36. Kong Q. Sulpiride clozapine combined high and low doses observed in the treatment of schizophrenia. Shandong Archives of Psychiatry. 2001;14:138-9.
37. Barbui C, Signoretti A, Mulè S, Boso M, Cipriani A. Does the addition of a second antipsychotic drug improve clozapine treatment? Schizophr Bull. 2009;35(2):458-68.
38. Taylor DM, Smith L. Augmentation of clozapine with a second antipsychotic - a meta-analysis of randomized, placebo-controlled studies. Acta Psychiatr Scand. 2009;119(6):419-25.
39. Barbui C, Accordini S, Nose M, Stroup S, Purgato M, Girlanda F, et al. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial. J Clin Psychopharmacol. 2011;31 (3):266-73.
40. Muscatello MRA, Bruno A, Pandolfo G, Micò U, Scimeca G, Di Nardo F, et al. Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. Schizophr Res. 2011;127(1-3):93-9.
41. Fleischhacker WW, Heikkinen ME, Olié J-P, Landsberg W, Dewaele P, McQuade RD, et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, doubleblind, placebo-controlled trial. Int J Neuropsychopharmacol. 2010;13(08):1115-25.
42. Chang J, Ahn Y, Park H, Lee K, Kim S, Kang U, et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2008;69(5):720-31. (Pubitemid 351838681)
43. Mitsonis CI, Dimopoulos NP, Mitropoulos PA, Kararizou EG, Katsa AN, Tsakiris FE, et al. Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: an open-label pilot study. Progr Neuro Psychopharmacol Biol Psychiatr. 2007;31(2):373-7. (Pubitemid 46210227)
44. Henderson DC, Kunkel L, Nguyen DD, Borba CP, Daley TB, Louie PM, et al. An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand. 2006;113(2):142-7. (Pubitemid 43340908)
45. Henderson DC, Fan X, Copeland PM, Sharma B, Borba CP, Boxill R, et al. Aripiprazole added to overweight and obese olanzapinetreated schizophrenia patients. J Clin Psychopharmacol. 2009;29 (2):165-9.
46. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004;64(20):2291-314. (Pubitemid 39388605)
47. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011;96(2):273-88.
48. Inoue T, Domae M, Yamada K, Furukawa T. Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl] butyloxy)-3,4-dihydro -2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J Pharmacol Exp Ther. 1996;277(1):137-43.
49. Newman-Tancredi A, Kleven M. Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5- HT1A receptor properties. Psychopharmacology. 2011;216(4):451-73.
50. Svensson K, Eriksson E, Carlsson A. Partial dopamine receptor agonists reverse behavioral, biochemical and neuroendocrine effects of neuroleptics in the rat: potential treatment of extrapyramidal side effects. Neuropharmacology. 1993;32(10):1037-45. (Pubitemid 23316511)
51. Hoffer Z, Roth R, Mathews M. Evidence for the partial dopaminereceptor agonist aripiprazole as a first-line treatment of psychosis in patients with iatrogenic or tumorogenic hyperprolactinemia. Psychosomatics. 2009;50:317-24.
52. Shim J, Shin J, Kelly D, Jung D, Seo Y, Liu K, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry. 2007;164(9):1404-10. (Pubitemid 47461141)
53. van Kooten M, Arends J, Cohen D. Preliminary report: a naturalistic study of the effect of aripiprazole addition on risperidonerelated hyperprolactinemia in patients treated with risperidone long-acting injection. J Clin Psychopharmacol. 2011;31(1):126-8.
54. Misawa F, Shimizu K, Fujii Y, Miyata R, Koshiishi F, Kobayashi M, et al. Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a crosssectional study. BMC Psychiatry. 2011;11(1):118.
55. Correll CU, Frederickson AM, Kane JM, Manu P. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res. 2007;89(1-3):91-100. (Pubitemid 44881290)
56. Di Sciascio G, Calo S, Amodio G, D'Onofrio S, Pollice R. The use of first generation versus second generation antipsychotics as addon or as switch treatment and its effect on QTC interval: the Italian experience in a real-world setting. Int J Immunopathol Pharmacol. 2011;24(1):225-30.
57. Auquier P, Lançon C, Rouillon F, Lader M, Holmes C. Mortality in schizophrenia. Pharmacoepidemiology and Drug Safety. 2006;15 (12):873-9. (Pubitemid 44941640)
58. Baandrup L, Gasse C, Jensen V, Glenthoj B, Nordentoft M, Lublin H, et al. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study. J Clin Psychiatry. 2010;1(2):103-8.
59. Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374(9690):620-7.
60. Zhu B, Ascher-Svanum H, Faries DE, Correll CU, Kane JM. Cost of antipsychotic polypharmacy in the treatment of schizophrenia. BMC Psychiatry. 2008;8:19.
61. Baandrup L, Sorensen J, Lublin H, Nordentoft M, Glenthoj B. Association of antipsychotic polypharmacy with health service cost: a register-based cost analysis. Eur J Health Econ. 2011.
62. Tamminga C. When is polypharmacy an advantage? Am J Psychiatry. 2011;168(7):663.
63. Byerly MJ, Marcus RN, Tran Q-V, Eudicone JM, Whitehead R, Baker RA. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. Schizophr Res. 2009;107(2-3):218-22.
64. Biedermann F, Fleischhacker WW. Emerging drugs for schizophrenia. Expert Opin Emerg Drugs. 2011;16(2):271-82.
65. Lewis DA, Sweet RA. Schizophrenia from a neural circuitry perspective: advancing toward rational pharmacological therapies. J Clin Invest. 2009;119(4):706-16.
66. Maayan N, Soares-Weiser K, Xia J, Adams CE. Antipsychotic combinations for schizophrenia. Cochrane Database Syst Rev. 2011, Protocols 2011(2).